We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals

205 hedge funds and large institutions have $2.51B invested in Agios Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 51 increasing their positions, 82 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 27

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

38% more capital invested

Capital invested by funds: $1.81B → $2.51B (+$695M)

10% more funds holding

Funds holding: 186205 (+19)

6% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $11.8M

7.91% less ownership

Funds ownership: 110.34%102.43% (-7.9%)

38% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 82

Holders
205
Holders Change
+19
Holders Change %
+10.22%
% of All Funds
2.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
48
Increased
51
Reduced
82
Closed
27
Calls
$12.4M
Puts
$11.8M
Net Calls
+$655K
Net Calls Change
+$3.67M
Name Holding Trade Value Shares
Change
Change in
Stake
Edgewood Management
101
Edgewood Management
Connecticut
$1.29M
Skandinaviska Enskilda Banken (SEB)
102
Skandinaviska Enskilda Banken (SEB)
Sweden
$1.26M
YIH
103
Y-Intercept (HK)
Hong Kong
$1.12M +$936K +25,945 New
Janus Henderson Group
104
Janus Henderson Group
United Kingdom
$1.12M -$133K -3,684 -12%
EGM
105
Engineers Gate Manager
New York
$1.11M -$388K -10,764 -29%
Qube Research & Technologies (QRT)
106
Qube Research & Technologies (QRT)
United Kingdom
$1.07M -$665K -18,414 -43%
Canada Life
107
Canada Life
Manitoba, Canada
$1.07M -$230K -6,369 -20%
TRCT
108
Tower Research Capital (TRC)
New York
$1.07M +$872K +24,171 +4,175%
Thrivent Financial for Lutherans
109
Thrivent Financial for Lutherans
Minnesota
$1.06M -$37.9K -1,051 -4%
Envestnet Asset Management
110
Envestnet Asset Management
Illinois
$1.06M +$4.11K +114 +0.5%
Citigroup
111
Citigroup
New York
$1.05M -$6.14M -170,163 -87%
SEI Investments
112
SEI Investments
Pennsylvania
$1.01M +$844K +23,378 New
TI
113
Tidal Investments
Wisconsin
$973K -$352K -9,767 -30%
AIM
114
Allen Investment Management
New York
$939K -$786K -21,790 -50%
NIM
115
NEOS Investment Management
Connecticut
$938K +$434K +12,021 +124%
Walleye Capital
116
Walleye Capital
New York
$859K -$4.56M -126,417 -86%
SRL
117
Scientech Research LLC
New Jersey
$759K +$635K +17,592 New
Handelsbanken Fonder
118
Handelsbanken Fonder
Sweden
$695K +$148K +4,100 +34%
State Board of Administration of Florida Retirement System
119
State Board of Administration of Florida Retirement System
Florida
$683K -$78.3K -2,170 -12%
PI
120
Pennant Investors
New Jersey
$651K
PA
121
Profund Advisors
Maryland
$637K -$720K -19,941 -57%
ASRS
122
Arizona State Retirement System
Arizona
$611K -$43.3K -1,201 -8%
HC
123
Henshaw Capital
Massachusetts
$605K +$5.74K +159 +1%
BHCM
124
Brevan Howard Capital Management
Jersey
$596K -$90.5K -2,507 -15%
Federated Hermes
125
Federated Hermes
Pennsylvania
$578K +$40K +1,108 +9%

AGIO Hedge Fund Activity: Q2 2024 in Review

205 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2024, worth a combined $2.51B — up 38% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new AGIO positions and 27 closed out — a net gain of 21 holders — while 51 added to existing stakes and 82 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $43M. The largest seller was State Street, cutting an estimated $36.9M.

  • 205 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2024, up from 186 in Q1 2024.
  • Funds reported $2.51B of Agios Pharmaceuticals stock for Q2 2024, up 38% quarter-over-quarter.
  • 48 funds opened new Agios Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of +21 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2024 was BVF Inc, an estimated $43M added.
  • The largest Agios Pharmaceuticals seller in Q2 2024 was State Street, an estimated $36.9M sold.

Based on aggregated 13F filings for Q2 2024.